AR‐V7 detected in circulating tumor cells (CTCs) has been reported as a biomarker for enzalutamide resistance,9 and nuclear‐localized AR‐V7 in CTCs may improve clinical decision‐making in selecting between ARSIs and taxanes.10 This evidence concerns the gene AR and neoplasm.